New partnership: Xilaplus® AF in Turkey
Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.
Xilaplus® AF is a Class IIa CE marked medical device specifically formulated for the control and reduction of diarrheal events of various etiologies. Xilaplus® AF acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhoea episodes and associated symptoms in adults, children, and infants.
This is a fantastic opportunity for both companies, considering the size of the Turkish antidiarrheals market and the innovation that Xilaplus® AF brings. We look forward to this exciting joint project.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.